PCSK9 inhibition
A 53-year-old woman with Lp(a) of 492 nmol/L, family history and coronary disease needing stenting, started on a PCSK9 inhibitor (Cureus 2026)
Original title: Chest Pain and Hidden Genetic Risk: A Case Report on the Role of Elevated Lipoprotein(a) in Early Cardiovascular Disease
This case report describes a 53-year-old woman presenting with chest pain and a family history of premature cardiovascular disease, found to have a markedly elevated lipoprotein(a) of 492 nmol/L and coronary artery disease requiring stenting. Despite adherence to high-intensity statin therapy, her LDL cholesterol remained above target, prompting initiation of a PCSK9 inhibitor for further LDL lowering. The authors use the case to reinforce European guideline recommendations for at least one lifetime Lp(a) measurement and note that targeted agents, including PCSK9 inhibitors and emerging nucleic-acid therapies such as zerlasiran, offer prospects for direct Lp(a) reduction. A single-patient report illustrating the current treatment gap rather than new evidence.
Original abstract
Lipoprotein(a) (Lp(a)) is increasingly recognized as a significant contributor to the risk of atherosclerotic cardiovascular disease (ASCVD). We report the case of a 53-year-old woman who presented with chest pain and has notable family history of premature cardiovascular events. Investigation revealed a markedly elevated Lp(a) level of 492 nmol/L, alongside the presence of coronary artery disease necessitating stenting. Despite adherence to high-intensity statin therapy, her low-density lipoprotein (LDL) cholesterol levels remained suboptimal. Consequently, we initiated treatment with a PCSK9 inhibitor to achieve further reductions in LDL cholesterol. This case underscores the importance of routinely measuring Lp(a), as recommended by European guidelines, which advocate for its assessment at least once during adulthood for effective risk stratification. While lifestyle interventions play a critical role in cardiovascular health, targeted therapies such as PCSK9 inhibitors and emerging nucleic acid-based treatments, including Zerlasiran, offer promising options for significantly lowering Lp(a) levels. Recognizing and addressing elevated Lp(a) is vital for identifying patients at high cardiovascular risk and for informing tailored management strategies aimed at improving patient outcomes.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.